D. E. Shaw & Co., Inc. Capricor Therapeutics, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding CAPR
# of Institutions
141Shares Held
17.2MCall Options Held
1.51MPut Options Held
1.02M-
Vanguard Group Inc Valley Forge, PA2.26MShares$25.7 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.25MShares$25.5 Million0.12% of portfolio
-
State Street Corp Boston, MA1.84MShares$20.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$18.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA901KShares$10.2 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $276M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...